Want to see PGEN full AI Analyst Report?
PGEN Stock Chart & Stats
$5.40
$0.17(3.15%)
At close: 4:00 PM EDT
$5.40
$0.17(3.15%)
Day’s Range― - ―
52-Week Range$1.57 - $6.04
Previous CloseN/A
Volume2.29M
Average Volume (3M)4.56M
Market Cap
$1.93B
Enterprise Value$1.41K
Total Cash (Recent Filing)$56.25M
Total Debt (Recent Filing)$98.25M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Aug 04, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding356,511,000
10 Day Avg. Volume3,165,004
30 Day Avg. Volume4,563,932
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)60.91
Price to Sales (P/S)131.52
P/FCF Ratio-14.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.50Price Target Upside131.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$124.32M
Bulls Say, Bears Say
Bulls Say
Commercial Launch MomentumA rapid revenue ramp from a first full commercial quarter shows the company can convert clinical assets into product sales. Durable launch momentum increases the chance of recurring product revenue, strengthens cash-generation potential, and supports reinvestment in commercialization and pipeline scaling over months.
Broad Payer Coverage & CodingExtensive payer coverage and a permanent J-code materially reduce reimbursement friction and simplify billing. Structural access across payers improves predictable uptake, shortens time-to-payment, and supports sustainable commercial economics as the therapy moves from niche to broader community settings.
Clinical Durability & Expert SupportDemonstrated durable responses and endorsement by key opinion leaders underpin long-term clinical adoption and guideline influence. This structural credibility increases prescriber confidence, supports label strength, and expands addressable market via planned pediatric and additional indication programs.
Bears Say
Heavy Cash BurnSustained negative operating and free cash flows require rapid margin improvement or external financing. Even with product revenue, quarter-to-quarter cash volatility and receivable timing leave runway dependent on collections or capital markets, increasing dilution and risking program pacing if cash use doesn't moderate.
High LeverageA materially higher debt load relative to equity reduces financial flexibility and raises refinancing risk while the company remains loss-making. Interest and principal obligations constrain free cash for R&D and commercialization, potentially forcing strategic compromises or dilutive capital raises if losses persist.
Low Gross Margins & LossesLow product gross margins and persistent operating losses imply limited per-unit profitability and a long path to self-sustaining cash flows. Elevated SG&A for commercialization and upcoming R&D spend (pediatric/redosing) mean margin expansion must be sustained to achieve the stated breakeven timeline.
Precigen News
PGEN FAQ
What was Precigen, Inc.’s price range in the past 12 months?
Precigen, Inc. lowest stock price was $1.57 and its highest was $6.04 in the past 12 months.
What is Precigen, Inc.’s market cap?
Precigen, Inc.’s market cap is $1.93B.
When is Precigen, Inc.’s upcoming earnings report date?
Precigen, Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 5 days.
How were Precigen, Inc.’s earnings last quarter?
Precigen, Inc. released its earnings results on May 13, 2026. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.034 by $0.014.
Is Precigen, Inc. overvalued?
According to Wall Street analysts Precigen, Inc.’s price is currently Undervalued.
Does Precigen, Inc. pay dividends?
Precigen, Inc. does not currently pay dividends.
What is Precigen, Inc.’s EPS estimate?
Precigen, Inc.’s EPS estimate is -0.01.
How many shares outstanding does Precigen, Inc. have?
Precigen, Inc. has 356,511,000 shares outstanding.
What happened to Precigen, Inc.’s price movement after its last earnings report?
Precigen, Inc. reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.034. Following the earnings report the stock price went up 10.843%.
Which hedge fund is a major shareholder of Precigen, Inc.?
Currently, no hedge funds are holding shares in PGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precigen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.50 (131.48% Upside)
$12.50 (131.48% Upside)
Blogger Sentiment
Bullish
PGEN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 10.9%
Last 30 Days ▼ 10.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
237.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.64%
Trailing 12-Months
Company Description
Precigen, Inc.
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
PGEN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum for PAPZIMEOS with a rapid revenue ramp, broad payer coverage, expert endorsement, and promising clinical durability data — all signaling an impactful product launch. The company also faces near-term operational challenges including elevated quarter cash burn, increased SG&A tied to commercialization, timing of cash collections, and limited disclosure of granular conversion metrics. Management expects cash consumption to moderate in Q2 and projects runway to cash-flow breakeven by end-2026, which, together with the strong launch indicators, supports a constructive outlook.View all PGEN earnings summariesPGEN Stock 12 Month Forecast
Average Price Target
$12.50
▲(131.48% Upside)
Technical Analysis
MiMedx Group
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
Immunome
―
Praxis Precision Medicines
―
Ownership Overview
35.60% Insiders
11.79% Mutual Funds
0.29% Other Institutional Investors
43.06% Public Companies and
Individual Investors